8 completed. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
Follow aclidinium bromide: new trials by email Literature Review of aclidinium bromide trials Research Report on aclidinium bromide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Aclidinium Bromide/Formoterol Fumarate 400/12μg BID - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | AstraZeneca | 20 | 2017-11-23 | 2019-07-22 |
| A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD Placebo, SUN101 3 mcg, SUN-101 6.25 mcg - COPD | Phase 2 | Completed | Sunovion Respiratory Development Inc. | 96 | 2014-01-01 | 2018-04-10 |
| Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Aclidinium/formoterol 400/12μg, Formoterol - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | AstraZeneca | 24 | 2012-01-01 | 2017-02-14 |
| Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients. Aclidinium bromide 100 μg bid, Aclidinium bromide 200 μg bid, Aclidininum bromide 400 μg bid - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | AstraZeneca | 79 | 2010-05-01 | 2017-01-09 |
| Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Aclidinium 200 μg / formoterol 12 μg, Placebo, Formoterol 12 μg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | AstraZeneca | 176 | 2010-02-01 | 2017-02-23 |
| Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo Aclidinium 400 μg / Formoterol 12 μg, Aclidinium 400 μg / Formoterol 6 μg, Aclidinium 400 μg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | AstraZeneca | 128 | 2009-12-01 | 2017-02-28 |
| Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients Aclidinium bromide 400 μg bid, Tiotropium 18 μg once-daily, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | AstraZeneca | 30 | 2009-03-01 | 2017-01-04 |
| Aclidinium/Formoterol Fixed Combination Dose Finding Study Aclidinium bromide and formoterol, Aclidinium bromide and formoterol placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | AstraZeneca | 808 | 2008-02-01 | 2016-11-16 |
Pulmonary Disease, Chronic Obstructive (8) · Emphysema (4) · Bronchiolitis Obliterans Syndrome (2) · Bronchitis (2) · Bronchitis, Chronic (2) · Smoking Cessation (1)
AstraZeneca (7) · Sunovion Respiratory Development Inc. (1)
United States (3) · Czechia (2) · Germany (2) · Australia (1) · Belgium (1) · China (1) · Poland (1) · Romania (1) · Russia (1)
Esther Garcia, MD (6) · Zhenxiang Yu (1)